Anatara Lifesciences (ASX:ANR) releases its latest institutional roadshow presentation and market update. This week CEO & Chairman Dr Mel Bridges and Co-Founder and Chief Scientific Officer (CSO) Dr Tracey Mynott will be conducting a roadshow updating existing and potential new institutional investors and analysts.
In late May, members of the executive team visited Japan to advance discussions with potential manufacturing and commercial partners for Progenza in Japan. We are pleased to report our meetings went well and we are on track to enter into our first significant partnering agreement in Japan by the end of September 2016.
Anatara Lifesciences Limited (ASX:ANR) Chief Scientific Officer, Dr. Tracy Mynott, speaks with Tom Piotrowski at CommSec's The Executive Series, by Commonwealth Bank Australia (ASX:CBA).
Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.
Cellmid Limited (ASX:CDY), in collaboration with a leading bone research group in Germany, has completed the first ever study showing that treatment with a midkine (MK) antibody accelerated bone fracture healing in an aged rodent model of the condition.
Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.
Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.
